| HOME >> BIOLOGY >> TECHNOLOGY |
Expenses:
Cost of sales 1,239 1,139 1,341
Research and development 5,064 4,116 3,368
Operating, general
and admin 4,757 4,418 3,722
Amortization of
intangibles 16 159 594
Amortization of
capital assets 254 287 315
Stock-based compensation 44 47 1,710
Interest income (645) (496) (270)
Foreign exchange
loss (gain) (327) (9) 16
Impairment of intangibles - 1,332 -
------------------------
10,402 10,993 10,796
Loss before income taxes (6,811) (7,569) (6,831)
Income taxes 153 105 108
------------------------
Loss for the year (6,964) (7,674) (6,939)
========================
Loss per share:
Basic (0.16) (0.22) (0.22)
Diluted (0.16) (0.22) (0.22)
Consolidated Statements of Cash Flows (thousand $)
--------------------------------------------------
2008 2007 2006
------------------------
Cash provided by (used in):
Loss for the year (6,964) (7,674) (6,939)
Items not involving cash:
Amortization of
capital assets 254 287 315
Amortization of intangibles 16 159 594
Stock-based compensation 44 47 1,710
Impairment of intangibles - 1,332 -
Foreign exchange
loss (gain) (327) (9) 16
'/>"/>
| SOURCE Helix BioPharma Corp. Copyright©2008 PR Newswire. All rights reserved |